The differentiation of megakaryocytes from human pluripotent stem cells in vitro offers
intriguing new perspectives for research and transfusion medicine. However, applications …

The production of megakaryocytes (MKs)—the precursors of blood platelets—from human
pluripotent stem cells (hPSCs) offers exciting clinical opportunities for transfusion medicine …

The production of blood cells and their precursors from human pluripotent stem cells
(hPSCs) in vitro has the potential to make a significant impact upon healthcare provision. We …

There exists a need to produce platelets in vitro for use in transfusion medicine, due to
increased platelet demands and short shelf life. Our lab uses human induced pluripotent …

Background Platelets are small anucleate cells that circulate in the blood in a resting state
but can be activated by external cues. In case of need, platelets from blood donors can be …

This invention relates to the forward programming of pluripotent stem cells (PSCs) into
megakaryocyte (MK) progenitor cells using the transcription factors GATA1, FLI1 and TAL1 …

Human pluripotent stem cells and in particular induced pluripotent stem cells (iPSC) derived
from adult tissue have recently opened novel and promising avenues for cell therapy. In vitro …

The process of hemostasis and blood coagulation relies heavily on a sufficient supply of
platelets (PLTs, also known as thrombocytes) within a person's bloodstream. Platelet …

Human embryonic stem cells (hESCs) represent a potential source of blood cells for
transfusion therapies and a promising tool for studying the ontogeny of hematopoiesis …

Embryonic stem cells and induced pluripotent stem cells offer promise for research and
treatment of hematologic diseases. While broad clinical application in humans is still a …